NOVAVAX Launches Phase I Clinical Trial of A/H5N1 Influenza Vaccine Candidate
The Phase I trial will enroll healthy adult subjects, each of whom will be randomized into one of six treatment groups including varying doses of A/H5N1 VLP vaccine, with or without Adjuvant 1, or placebo. The trial is being conducted in a stepwise manner, enrolling increasing number of subjects, until a target of approximately 333 subjects is reached. All subjects will be evaluated for safety and immunogenicity. Trial participants will receive two identical intramuscular injections at a 21-day interval (Day 0 and Day 21) with study follow-up approximately 13 months from the first dose.
Statements herein relating to the future of
Frederick W. DriscollVP, Chief Financial Officer and Treasurer Novavax, Inc.240-268-2000